
The study evaluated proptosis reduction from teprotumumab treatment as a percentage of pre-treatment proptosis. Among 119 patients, the reduction averaged 14.4% or 3.3 mm. Reporting as a percentage-based reduction offers better clinical insight into teprotumab's effectiveness.
Like
Save
Share